|
Dostarlimab Clinical Trials
23 actively recruiting trials across 8 locations
▲ +1 trial since May 2026
Also known as: GSK4057190A, Jemperli, TSR-042
Pipeline
Phase 1: 2Phase 2: 14Phase 3: 3Phase 1/2: 3
Top Sponsors
- GlaxoSmithKline7
- M.D. Anderson Cancer Center2
- Yonsei University1
- University of Iowa1
- University Health Network, Toronto1
Indications
- Cancer23
- Neoplasms, Colon2
- Gastric Adenocarcinoma2
- Endometrial Cancer2
- Neoplasms, Head and Neck1
Other14 trials
Houston, Texas2 trials
Tucson, Arizona1 trial
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GSK Investigational Site
Phase 3
Jonesboro, Arkansas1 trial
La Jolla, California1 trial
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors
GSK Investigational Site
Phase 1/2
Stanford, California1 trial
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
GSK Investigational Site
Phase 1
Tampa, Florida1 trial
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Moffitt Cancer Center
Phase 2
Iowa City, Iowa1 trial
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
University of Iowa Hospitals & Clinics
Phase 2
Basking Ridge, New Jersey1 trial
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Basking Ridge (All Protocol Activites)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.